96. Crohn disease Clinical trials / Disease details

Clinical trials : 2,400 / Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-000852-32-NL (EUCTR)	30/01/2020	08/10/2019	A preliminary study of Low Dose Naltrexone for the induction of remission in patients with mild to moderate Crohn’s Disease that failed conventional treatment: The LDN Crohn study.	A preliminary study of Low Dose Naltrexone for the induction of remission in patients with mild to moderate Crohn’s Disease that failed conventional treatment: The LDN Crohn study. - The LDN Crohn study	Inflammatory Bowel Disease, Crohn's disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Naltrexone hydrochloride	ErasmusMC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	122	Phase 2	Netherlands
2	NCT01810185 (ClinicalTrials.gov)	March 2013	11/3/2013	Low Dose Naltrexone in Symptomatic Inflammatory Bowel Disease	Low Dose Naltrexone in Symptomatic Inflammatory Bowel Disease	Inflammatory Bowel Disease;Crohn's Disease;Ulcerative Colitis	Drug: Low dose naltrexone;Drug: Placebo	Santa Barbara Cottage Hospital	NULL	Withdrawn	18 Years	N/A	Both	0	Phase 2	United States
3	NCT00715117 (ClinicalTrials.gov)	July 2008	14/7/2008	The Efficacy of Low Dose Naltrexone Therapy in Children With Crohn's Disease	The Efficacy of Low Dose Naltrexone Therapy in Children With Crohn's Disease	Crohn's Disease	Drug: Naltrexone;Other: Placebo, sugar pill	Milton S. Hershey Medical Center	NULL	Completed	6 Years	17 Years	All	14	Phase 2	United States